Regulus Therapeutics Inc.

RGLS · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$46,358-$30,037-$28,323-$27,808
Dep. & Amort.-$1,210$227$122$459
Deferred Tax$0$0$0-$662
Stock-Based Comp.$7,735$2,801$2,177$2,923
Change in WC-$1,882$257$550$914
Other Non-Cash$42-$16-$52$46
Operating Cash Flow-$41,673-$26,768-$25,526-$24,128
Investing Activities
PP&E Inv.-$340-$613-$361-$251
Net Acquisitions$0$3$15$0
Inv. Purchases-$83,643-$4,899-$32,759$0
Inv. Sales/Matur.$48,000$20,000$18,000$0
Other Inv. Act.$0$0-$15$0
Investing Cash Flow-$35,983$14,491-$15,120-$251
Financing Activities
Debt Repay.-$1,377-$3,304$0-$80
Stock Issued$93,794$15,120$4,491$53,791
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$3$0$0$26
Financing Cash Flow$92,417$11,816$4,491$53,737
Forex Effect$0$0$0$0
Net Chg. in Cash$14,761-$461-$36,155$29,358
Supplemental Information
Beg. Cash$23,829$24,290$60,445$31,087
End Cash$38,590$23,829$24,290$60,445
Free Cash Flow-$42,013-$27,381-$25,887-$24,379